Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy

Gianluca Manni, Marco Centofanti, Marta Sacchetti, Francesco Oddone, Stefano Bonini, Mariacristina Parravano, Massimo Gilberto Bucci

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: To identify demographic and clinical characteristics associated with the development of brimonidine tartrate 0.2%-induced ocular allergy. Patients and Methods: In this retrospective study, 133 patients affected by primary open-angle, pigmentary, narrow angle, or pseudo-exfoliative glaucoma and treated with brimonidine tartrate 0.2% were divided into two groups: allergic and non allergic to brimonidine tartrate 0.2%. The distribution of demographic (age and sex), local (history of allergic conjunctivitis, previous eye-drop ocular allergy, use of other concurrent topical medications, amount of topical medications previously used, use of contact lenses, and tear film production), and systemic (history of systemic allergies and use of systemic drugs) factors was evaluated by comparing the brimonidine tartrate 0.2% allergic and the non-allergic groups. Results: In this study, 13.5% of patients (18 of 133) developed brimonidine ocular allergy generally within two weeks from the beginning of treatment (mean time 14.8 ± 17.9 days). The brimonidine tartrate 0.2% allergic group showed a significantly higher frequency of history of ocular allergy to eye-drops (P = 0.048) and to topical beta-blockers (P = 0.019) when compared with the brimonidine tartrate 0.2% non-allergic group. Moreover, the allergic group showed a decreased tear film production (P = 0.044). Conclusion: This study showed that history of eye-drop allergies and reduction of tear film production were more frequently associated with the development of brimonidine tartrate 0.2%-induced ocular allergy.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalJournal of Glaucoma
Volume13
Issue number2
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Hypersensitivity
Demography
Ophthalmic Solutions
Tears
Allergic Conjunctivitis
Sex Distribution
Brimonidine Tartrate
Contact Lenses
Age Distribution
Glaucoma
Retrospective Studies
Pharmaceutical Preparations

Keywords

  • Brimonidine
  • Drug toxicity
  • Glaucoma

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy. / Manni, Gianluca; Centofanti, Marco; Sacchetti, Marta; Oddone, Francesco; Bonini, Stefano; Parravano, Mariacristina; Bucci, Massimo Gilberto.

In: Journal of Glaucoma, Vol. 13, No. 2, 04.2004, p. 163-167.

Research output: Contribution to journalArticle

Manni, Gianluca ; Centofanti, Marco ; Sacchetti, Marta ; Oddone, Francesco ; Bonini, Stefano ; Parravano, Mariacristina ; Bucci, Massimo Gilberto. / Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy. In: Journal of Glaucoma. 2004 ; Vol. 13, No. 2. pp. 163-167.
@article{a700b233a177405d8705119ccbce1ff3,
title = "Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2{\%}-Induced Ocular Allergy",
abstract = "Purpose: To identify demographic and clinical characteristics associated with the development of brimonidine tartrate 0.2{\%}-induced ocular allergy. Patients and Methods: In this retrospective study, 133 patients affected by primary open-angle, pigmentary, narrow angle, or pseudo-exfoliative glaucoma and treated with brimonidine tartrate 0.2{\%} were divided into two groups: allergic and non allergic to brimonidine tartrate 0.2{\%}. The distribution of demographic (age and sex), local (history of allergic conjunctivitis, previous eye-drop ocular allergy, use of other concurrent topical medications, amount of topical medications previously used, use of contact lenses, and tear film production), and systemic (history of systemic allergies and use of systemic drugs) factors was evaluated by comparing the brimonidine tartrate 0.2{\%} allergic and the non-allergic groups. Results: In this study, 13.5{\%} of patients (18 of 133) developed brimonidine ocular allergy generally within two weeks from the beginning of treatment (mean time 14.8 ± 17.9 days). The brimonidine tartrate 0.2{\%} allergic group showed a significantly higher frequency of history of ocular allergy to eye-drops (P = 0.048) and to topical beta-blockers (P = 0.019) when compared with the brimonidine tartrate 0.2{\%} non-allergic group. Moreover, the allergic group showed a decreased tear film production (P = 0.044). Conclusion: This study showed that history of eye-drop allergies and reduction of tear film production were more frequently associated with the development of brimonidine tartrate 0.2{\%}-induced ocular allergy.",
keywords = "Brimonidine, Drug toxicity, Glaucoma",
author = "Gianluca Manni and Marco Centofanti and Marta Sacchetti and Francesco Oddone and Stefano Bonini and Mariacristina Parravano and Bucci, {Massimo Gilberto}",
year = "2004",
month = "4",
doi = "10.1097/00061198-200404000-00014",
language = "English",
volume = "13",
pages = "163--167",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy

AU - Manni, Gianluca

AU - Centofanti, Marco

AU - Sacchetti, Marta

AU - Oddone, Francesco

AU - Bonini, Stefano

AU - Parravano, Mariacristina

AU - Bucci, Massimo Gilberto

PY - 2004/4

Y1 - 2004/4

N2 - Purpose: To identify demographic and clinical characteristics associated with the development of brimonidine tartrate 0.2%-induced ocular allergy. Patients and Methods: In this retrospective study, 133 patients affected by primary open-angle, pigmentary, narrow angle, or pseudo-exfoliative glaucoma and treated with brimonidine tartrate 0.2% were divided into two groups: allergic and non allergic to brimonidine tartrate 0.2%. The distribution of demographic (age and sex), local (history of allergic conjunctivitis, previous eye-drop ocular allergy, use of other concurrent topical medications, amount of topical medications previously used, use of contact lenses, and tear film production), and systemic (history of systemic allergies and use of systemic drugs) factors was evaluated by comparing the brimonidine tartrate 0.2% allergic and the non-allergic groups. Results: In this study, 13.5% of patients (18 of 133) developed brimonidine ocular allergy generally within two weeks from the beginning of treatment (mean time 14.8 ± 17.9 days). The brimonidine tartrate 0.2% allergic group showed a significantly higher frequency of history of ocular allergy to eye-drops (P = 0.048) and to topical beta-blockers (P = 0.019) when compared with the brimonidine tartrate 0.2% non-allergic group. Moreover, the allergic group showed a decreased tear film production (P = 0.044). Conclusion: This study showed that history of eye-drop allergies and reduction of tear film production were more frequently associated with the development of brimonidine tartrate 0.2%-induced ocular allergy.

AB - Purpose: To identify demographic and clinical characteristics associated with the development of brimonidine tartrate 0.2%-induced ocular allergy. Patients and Methods: In this retrospective study, 133 patients affected by primary open-angle, pigmentary, narrow angle, or pseudo-exfoliative glaucoma and treated with brimonidine tartrate 0.2% were divided into two groups: allergic and non allergic to brimonidine tartrate 0.2%. The distribution of demographic (age and sex), local (history of allergic conjunctivitis, previous eye-drop ocular allergy, use of other concurrent topical medications, amount of topical medications previously used, use of contact lenses, and tear film production), and systemic (history of systemic allergies and use of systemic drugs) factors was evaluated by comparing the brimonidine tartrate 0.2% allergic and the non-allergic groups. Results: In this study, 13.5% of patients (18 of 133) developed brimonidine ocular allergy generally within two weeks from the beginning of treatment (mean time 14.8 ± 17.9 days). The brimonidine tartrate 0.2% allergic group showed a significantly higher frequency of history of ocular allergy to eye-drops (P = 0.048) and to topical beta-blockers (P = 0.019) when compared with the brimonidine tartrate 0.2% non-allergic group. Moreover, the allergic group showed a decreased tear film production (P = 0.044). Conclusion: This study showed that history of eye-drop allergies and reduction of tear film production were more frequently associated with the development of brimonidine tartrate 0.2%-induced ocular allergy.

KW - Brimonidine

KW - Drug toxicity

KW - Glaucoma

UR - http://www.scopus.com/inward/record.url?scp=1642399896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642399896&partnerID=8YFLogxK

U2 - 10.1097/00061198-200404000-00014

DO - 10.1097/00061198-200404000-00014

M3 - Article

VL - 13

SP - 163

EP - 167

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 2

ER -